---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-039903"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:23:23.950161+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# CorMedix Q1 2025 net revenue $39.1M, net income $20.6M vs loss; raises H1 guidance to high-end

## Summary
- Q1 net revenue $39.1M; net income $20.6M ($0.32 EPS) vs net loss of $14.5M ($0.25 loss) in Q1 2024.
- Adjusted EBITDA $23.6M; cash from operations $19.7M; cash and short-term investments $77.5M at March 31.
- Expects to be at high-end of H1 2025 net sales guidance of $62M-$70M based on current order trends.
- Inpatient sales team fully staffed; DefenCath inpatient shipments doubled in last 3 months; Phase 3 TPN-CLABSI study started.

## SEC filing metadata
- accession: 0001213900-25-039903
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390025039903/0001213900-25-039903-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390025039903/ea0240827-8k_cormedix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-039903
- JSON: https://secwatch.observer/filing/0001213900-25-039903.json
- Plain text: https://secwatch.observer/filing/0001213900-25-039903.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.